Annual ROE
-49.50%
-11.74%-31.09%
December 31, 2023
Summary
- As of February 26, 2025, CCCC annual return on equity is -49.50%, with the most recent change of -11.74% (-31.09%) on December 31, 2023.
- During the last 3 years, CCCC annual ROE has risen by +29.08% (+37.01%).
- CCCC annual ROE is now -262.51% below its all-time high of 30.46%, reached on December 31, 2019.
Performance
CCCC ROE Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly ROE
-43.59%
+1.31%+2.92%
September 30, 2024
Summary
- As of February 26, 2025, CCCC quarterly return on equity is -43.59%, with the most recent change of +1.31% (+2.92%) on September 30, 2024.
- Over the past year, CCCC quarterly ROE has increased by +7.53% (+14.73%).
- CCCC quarterly ROE is now -138.37% below its all-time high of 113.59%, reached on September 30, 2020.
Performance
CCCC Quarterly ROE Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
ROE Formula
ROE = Net Income
Shareholders Equity ✕ 100%
Shareholders Equity ✕ 100%
CCCC ROE Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -31.1% | +14.7% |
| 3 y3 years | +37.0% | +14.7% |
| 5 y5 years | -351.3% | +14.7% |
CCCC ROE Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -97.8% | at low | -81.8% | +17.9% |
| 5 y | 5-year | -262.5% | +37.0% | -138.4% | +94.0% |
| alltime | all time | -262.5% | +37.0% | -138.4% | +94.0% |
C4 Therapeutics ROE History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | -43.59%(-2.9%) |
| Jun 2024 | - | -44.90%(-13.3%) |
| Mar 2024 | - | -51.81%(-2.4%) |
| Dec 2023 | -49.50%(+31.1%) | -53.10%(+3.9%) |
| Sep 2023 | - | -51.12%(+5.9%) |
| Jun 2023 | - | -48.28%(+16.1%) |
| Mar 2023 | - | -41.59%(+10.7%) |
| Dec 2022 | -37.76% | -37.56%(+27.9%) |
| Sep 2022 | - | -29.37%(+13.1%) |
| Jun 2022 | - | -25.96%(+0.7%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2022 | - | -25.79%(+7.5%) |
| Dec 2021 | -25.03%(-68.1%) | -23.98%(-35.9%) |
| Sep 2021 | - | -37.39%(-20.3%) |
| Jun 2021 | - | -46.93%(-50.2%) |
| Mar 2021 | - | -94.15%(-51.5%) |
| Dec 2020 | -78.58%(-358.0%) | -194.13%(-270.9%) |
| Sep 2020 | - | 113.59%(-115.7%) |
| Jun 2020 | - | -724.69%(-2633.0%) |
| Mar 2020 | - | 28.61%(+59.2%) |
| Dec 2019 | 30.46%(+54.6%) | 17.97% |
| Dec 2018 | 19.70% | - |
FAQ
- What is C4 Therapeutics annual return on equity?
- What is the all time high annual ROE for C4 Therapeutics?
- What is C4 Therapeutics annual ROE year-on-year change?
- What is C4 Therapeutics quarterly return on equity?
- What is the all time high quarterly ROE for C4 Therapeutics?
- What is C4 Therapeutics quarterly ROE year-on-year change?
What is C4 Therapeutics annual return on equity?
The current annual ROE of CCCC is -49.50%
What is the all time high annual ROE for C4 Therapeutics?
C4 Therapeutics all-time high annual return on equity is 30.46%
What is C4 Therapeutics annual ROE year-on-year change?
Over the past year, CCCC annual return on equity has changed by -11.74% (-31.09%)
What is C4 Therapeutics quarterly return on equity?
The current quarterly ROE of CCCC is -43.59%
What is the all time high quarterly ROE for C4 Therapeutics?
C4 Therapeutics all-time high quarterly return on equity is 113.59%
What is C4 Therapeutics quarterly ROE year-on-year change?
Over the past year, CCCC quarterly return on equity has changed by +7.53% (+14.73%)